Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5111 - AG-120, a novel IDH1 targeted molecule, inhibits invasion and migration of chondrosarcoma cells in vitro.

Date

11 Sep 2017

Session

Poster display session

Presenters

VICTORIA HEREDIA

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

V. HEREDIA1, M. Mendiola2, E. Ortiz3, D. Bernabéu4, J.J. Pozo-Kreilinger5, M. Miguel1, R. Crespo6, A. Berjón5, V. Martínez-Marín7, A. Redondo7

Author affiliations

  • 1 Molecular Pathology And Therapeutic Targets Laboratory, IdIPAZ – Hospital Universitario La Paz, 28046 - Madrid/ES
  • 2 Molecular Pathology And Therapeutic Targets Laboratory, IdIPAZ – Hospital Universitario La Paz, Madrid/ES
  • 3 Orthopedic Traumatology Surgery Department, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 4 Radiology Department, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 5 Pathology Department, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 6 Translational Oncology, IdIPAZ – Hospital Universitario La Paz, Madrid/ES
  • 7 Medical Oncology Department, Hospital Universitario La Paz, 28046 - Madrid/ES
More

Resources

Abstract 5111

Background

Chondrosarcoma (CS) is the second most frequent primary malignant bone tumor in adults. Surgery is the best treatment option for these patients since most subtypes are resistant to chemotherapy and radiotherapy, thus novel systemic therapies are needed for patients with unresectable tumors. The majority of cases correspond to the conventional central CS histology, were recurrent mutations in isocitrate dehydrogenases (IDH1/2) coding genes are found. Therefore, IDH1 has been reported as a potential therapeutic target and several selective inhibitor molecules, such as AGI-5198 and, more recently, AG-120, have been developed and are currently being evaluated in clinical trials. In this work, we have explored the in vitro effects of AG-120 on a central CS cell line, JJ012, which carries a mutation in IDH1.

Methods

JJ012 cells were cultured both in monolayer and three-dimensional (3D) spheroids and treated with increasing concentrations of AG-120. IDH1 mutation in arginine residue R132G was verified by PCR sequencing. Proliferation and cytotoxic screening were done with Sulforhodamine B (SRB) assay. Monolayer invasion and migration assays were performed with FluoroBlok and wound healing assays respectively and 3D experiments were developed using a Matrigel matrix.

Results

R132G mutation of IDH1 was confirmed by PCR sequencing. Previous reports with AGI-5198 inhibitor show contradictory results regarding their effect on CS cells. In this work, we show how novel molecule AG-120 inhibits both invasion and migration of CS IDH1 mutated JJ012 cell line in monolayer and 3D cell culture, although it does not affect their proliferation. Minor effects on viability were only detected at high dose (100 µM).

Conclusions

These results support AG-120 as a new possible therapeutic agent for patients with metastatic CS, and further research is needed to understand its action mechanisms in this pathology.

Clinical trial identification

Legal entity responsible for the study

Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP)

Funding

Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.